yahoo_financeOriginal article
MAIA Biotechnology Says Ateganosine Shows 90.5% Disease Control Rate in Phase 2 Expansion Trial
Phase 2positiveAteganosinePositive
AI Analysis
Summary
MAIA Biotechnology announced that ateganosine achieved a 90.5% disease control rate in a Phase 2 expansion trial. This positive Phase 2 data represents a meaningful clinical milestone for the investigational therapy.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
90.5% disease control rate in Phase 2 expansion trial
Importance:6/10
Sentiment:
0.75
Phase 2clinical trialdisease controlexpansion trial
Related Companies
Read the original article
Published by yahoo_finance on July 8, 2026 2:32 PM